Blueprint
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 26, 2016
 
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
Maryland
 
001-14494
 
33-0724736
(State or other jurisdiction
 of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
10 North Park Place, Suite 201
Morristown, NJ
 
 
07960
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (800) 793-2145
 
__________________________________________________________________
  (Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
☐
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
☐
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
 
☐
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
 
Item 5.07        Submission of Matters to a Vote of Security Holders
 
The annual meeting of stockholders of Pernix Therapeutics Holdings, Inc. (the “Company”) was held on May 26, 2016.  At the annual meeting, our stockholders (i) elected each nominee to serve as a Company director until the next annual meeting of stockholders, (ii) approved, on an advisory basis, the Company’s executive compensation, (iii) ratified the selection of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016 and (iv) approved a stockholder proposal concerning majority voting in uncontested elections of directors.
 
  The final voting tabulation for the election of directors was as follows:
 
Nominee
 
Number of Votes For
 
Number of Votes Against
Steven A. Elms
 
13,405,944
 
2,245,103
Tasos G. Konidaris
 
13,863,438
 
1,787,609
John A. Sedor
 
7,277,376
 
8,373,671
 
The final voting tabulation for the approval, on an advisory basis, of the Company’s executive compensation was as follows:
 
Proposal
 
Number of Votes For
 
Number of Votes Against
 
Abstentions
Approval, on an advisory basis, the Company’s executive compensation
 
13,754,735
 
1,780,482
 
115,830
 
The final voting tabulation for the ratification of the independent registered public accounting firm was as follows:
 
Proposal
 
Number of Votes For
 
Number of Votes Against
 
Abstentions      
Ratification of Cherry Bekaert LLP
 
38,624,579
 
1,477,882
 
62,761
 
 
The final voting tabulation for the approval of a stockholder proposal concerning majority voting in uncontested elections of directors was as follows:
 
Proposal
 
Number of Votes For
 
Number of Votes Against
 
Abstentions
Approval of stockholder proposal
 
14,527,026
 
509,073
 
614,948
 
 
 
2
 
 
SIGNATURE
 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PERNIX THERAPEUTICS HOLDINGS, INC.
 
 
 
 
 
Dated:  May 31, 2016
By:
 /s/ Sanjay Patel
 
 
 
Sanjay Patel
 
 
 
Chief Financial Officer
 
 
 
 
 
 
 
3